Education
About Us
Working with TipRanks
Follow Us
BioMarin Pharmaceutical (DE:BM8)
FRANKFURT:BM8
RESEARCH TOOLSreports
BM8 Stock Chart & Stats
Day’s Range― - ―
52-Week Range€49.15 - €84.16
Previous CloseN/A
Volume0.00
Average Volume (3M)9.00
Market Cap
$10.08B
Enterprise Value€13.23B
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)21.6
Beta0.38
Next Earnings
Aug 05, 2025EPS Estimate
0.74Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.84
Shares Outstanding191,775,670
10 Day Avg. Volume18
30 Day Avg. Volume9
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.00
Price to Cash Flow (P/CF)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap1.31
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda17.91
Forecast
1Y Price Target
$85.85Price Target Upside61.12% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering21
---
BioMarin Pharmaceutical News
PremiumCompany Announcements
BioMarin Pharmaceuticals Reports Strong Q1 2025 Earnings
PremiumCompany Announcements
BioMarin’s Strong Q1 2025 Performance and Growth Outlook
---
Bulls Say, Bears Say
Bulls Say
Drug DevelopmentThe Phase III PEGASUS trial of Palynziq in adolescents with phenylketonuria met its primary endpoint, demonstrating a significant lowering in blood Phe levels compared to diet alone.
EarningsBioMarin's first quarter revenue of $745 million, a year-over-year increase of 15%, beat both the estimate of $735.6 million and consensus of $738.1 million.
Sales GrowthVoxzogo's growth continues to be strong with a 40% year-over-year increase.
Bears Say
Market CompetitionEmerging therapies with competitive risk/benefit profiles, such as PTC’s sepiapterin, could pose a competitive threat to Palynziq in the market.
Revenue VariabilityThere was a modest quarter-over-quarter revenue decline due to the complexity of market dynamics and the variability of ex-U.S. government orders.
Safety ConcernsThere is uncertainty about safety results due to the existing black-box warning for Palynziq, which could affect investor perception.
---
Options Prices
Currently, No data available
---
Ownership Overview
1.00% Insiders
36.97%
Mutual Funds
0.94% Other Institutional Investors
38.53% Public Companies and
Individual Investors
BM8 FAQ
What was BioMarin Pharmaceutical’s price range in the past 12 months?
BioMarin Pharmaceutical lowest stock price was €49.15 and its highest was €84.16 in the past 12 months.
What is BioMarin Pharmaceutical’s market cap?
BioMarin Pharmaceutical’s market cap is $10.08B.
When is BioMarin Pharmaceutical’s upcoming earnings report date?
BioMarin Pharmaceutical’s upcoming earnings report date is Aug 05, 2025 which is in 88 days.
How were BioMarin Pharmaceutical’s earnings last quarter?
BioMarin Pharmaceutical released its earnings results on May 01, 2025. The company reported €0.838 earnings per share for the quarter, beating the consensus estimate of €0.602 by €0.236.
Is BioMarin Pharmaceutical overvalued?
According to Wall Street analysts BioMarin Pharmaceutical’s price is currently Undervalued.
Does BioMarin Pharmaceutical pay dividends?
BioMarin Pharmaceutical does not currently pay dividends.
What is BioMarin Pharmaceutical’s EPS estimate?
BioMarin Pharmaceutical’s EPS estimate is 0.74.
How many shares outstanding does BioMarin Pharmaceutical have?
BioMarin Pharmaceutical has 191,775,670 shares outstanding.
What happened to BioMarin Pharmaceutical’s price movement after its last earnings report?
BioMarin Pharmaceutical reported an EPS of €0.838 in its last earnings report, beating expectations of €0.602. Following the earnings report the stock price went up 6.456%.
Which hedge fund is a major shareholder of BioMarin Pharmaceutical?
Currently, no hedge funds are holding shares in DE:BM8
---
BioMarin Pharmaceutical Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$85.85 (61.12% Upside)
$85.85 (61.12% Upside)
Blogger Sentiment
Bullish
DE:BM8 Sentiment 100%
Sector Average 71%
Sector Average 71%
Insider Transactions
Sold Shares
Worth $501.3K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-28.16%
12-Months-Change
Fundamentals
Return on Equity
9.64%
Trailing 12-Months
Asset Growth
3.99%
Trailing 12-Months
Company Description
BioMarin Pharmaceutical
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops valoctocogene roxaparvovec, an adeno associated virus vector, which is in Phase III clinical trial for the treatment of patients with severe hemophilia A; BMN 307, an AAV5 mediated gene therapy, which is in Phase 1/2 clinical trial to normalize blood Phe concentration levels in patients with PKU; and BMN 255 that is in Phase 1/2 clinical trial for treating primary hyperoxaluria. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has license and collaboration agreements with Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc., and Asubio Pharma Co., Ltd. The company was incorporated in 1996 and is headquartered in San Rafael, California.
---
BM8 Company Deck
---
BM8 Earnings Call
Q1 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
BioMarin reported strong financial performance with notable revenue growth and profitability expansion, supported by successful pipeline progress. However, potential challenges include analyzing exposure to future pharmaceutical tariffs and managing VOXZOGO's revenue dynamics amid global order patterns. The overall sentiment leans towards optimism with strategic growth initiatives and robust financial results.Read More>---
BM8 Revenue Breakdown
28.98% VIMIZIM
19.42% VOXZOGO
17.37% NAGLAZYME
12.56% PALYNZIQ
21.66% Other
---
BM8 Stock 12 Month Forecast
Average Price Target
€85.85
▲(61.12% Upside)
Technical Analysis
---